 ROCKVILLE, Md., Oct. 6, 2021 PRNewswire -- Synthetic Biologics, Inc. NYSE American: SYN, a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal GI diseases in areas of high unmet need, today announced the Companys reconvened annual meeting of shareholders, on October 6, 2021, at 9:30 a.m. 